
30 patients with CBF-AML
13 patients with t(8;21) received 1 cycle of VEN+HMA treatment
17 patients with inv(16)/t(16;16) received 1 cycle of VEN+HMA treatment
4 CR/CRi
4 PR
5 NR
17 CR/CRi
4 received ID/HD AraC-based consolidation chemotherapy
1 completed treatment
1 relapsed, received reinduction and allo-HSCT
1 died due to infection
1 was during consolidation chemotherapy
2 received second cycle of VEN+HMA
1 achieved CR and received ID/HD AraC-based consolidation chemotherapy
1 failed and died due to infection
2 received traditional chemotherapy and both achieved CR/CRi
1 proceeded to allo-HSCT
1 received ID/HD AraC-based consolidation therapy
5 received traditional salvage chemotherapy and all achieved CR/CRi, followed by ID/HD AraC-based consolidation chemotherapy
1 completed treatment
1 was during consolidation chemotherapy
2 proceeded to allo-HSCT
1 relapsed, received reinduction and allo-HSCT
17 received ID/HD AraC-based consolidation chemotherapy
3 proceeded to allo-HSCT
1 relapsed, received reinduction and allo-HSCT